Fundz

Who to call at Celosia Therapeutics, and when

Fundz watches for the moments Celosia Therapeutics starts buying, and tells you who to reach.

  • An alert the day Celosia Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Celosia Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Celosia Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease, secured a $2 million grant from NSW government's Emerging Technology Commercialisation Fund.

Nov 18, 2026
New South WalesBiotechnologyHealth CareTherapeutics

Description

Celosia Therapeutics has been awarded a $2 million grant from the NSW government's new Emerging Technology Commercialisation Fund, the largest grant in the first round of the program. The funding will support expansion of Celosia's MND pipeline, including candidate development, manufacturing work, and preclinical studies for its lead program CTx1000. Celosia will collaborate with the NSW Viral Vector Manufacturing Facility over two years to develop manufacturing processes for a new gene therapy candidate. The biotech, which previously raised $16.75 million in a Series A round in 2024, is developing treatments for motor neurone disease based on research into the TDP-43 protein.

Quick answer

Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease, secured a $2 million grant from NSW government's Emerging Technology Commercialisation Fund. (November 18, 2026). Celosia Therapeutics is based in New South Wales, Australia.

What agreement did Celosia Therapeutics announce on November 18, 2026?
Celosia Therapeutics has been awarded a $2 million grant from the NSW government's new Emerging Technology Commercialisation Fund, the largest grant in the first round of the program. The funding will support expansion of Celosia's MND pipeline, including candidate development, manufacturing work, and preclinical studies for its lead program CTx1000.
What does Celosia Therapeutics do?
Celosia Therapeutics is a Macquarie University spinout developing gene therapies for motor neurone disease (MND), specifically amyotrophic lateral sclerosis (ALS).
Where is Celosia Therapeutics based?
Celosia Therapeutics is based in New South Wales, Australia.
Which similar companies announced agreements around the same time?
AstraZeneca Pharma India (November 17, 2026), Innate Pharma (November 15, 2026), Pfizer (November 14, 2026) and Sino Biopharmaceutical (November 13, 2026) also announced agreements within 45 days of Celosia Therapeutics.

Source: Fundz verified event record.

Other recent agreements in Therapeutics and Biotechnology

Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.

Company Information

Company

Celosia Therapeutics

Location

New South Wales, Australia

About

Celosia Therapeutics is a Macquarie University spinout developing gene therapies for motor neurone disease (MND), specifically amyotrophic lateral sclerosis (ALS). The company's lead program, CTx1000, is designed to help nerve cells clear toxic protein clumps while preserving healthy proteins needed for cell function. Celosia is currently conducting clinical trials and recently raised $16.75 million in Series A funding.

Predictive Intelligence
Strategic

ML-powered predictions for Celosia Therapeutics's next move

Learn about Strategic plan

Celosia Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.